Author:
O’Brien Sheila F.,Ehsani-Moghaddam Behrouz,Osmond Lori,Fan Wenli,Goldman Mindy,Drews Steven J.
Publisher
Springer Science and Business Media LLC
Reference64 articles.
1. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. https://www.who.int/publications/i/item/combating-hepatitis-b-and-c-to-reach-elimination-by-2030 Accessed 5 Oct 2023.
2. Snell G, Marshall AD, van Gennip J, Butler-McPhee J, Cooper CL, Kronfi N, et al. Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: a descriptive study. Can Liv J. 2023;6:190–200.
3. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Int Med. 2017;166:637–48.
4. Feld JJ, Jacobson IM, Hezode T, Asselah PJ, Ruane N, Gruener A, et al. Sofosbuvir and velpatasvir for HCV genotype 1,2,4,5, and6 infection. New Engl J Med. 2015;373:2599–607.
5. Popovic N, Williams A, Perinet S, Campeau L, Yang Q, Zhang F, et al. National Hepatitis C estimates: incidence, prevalence, undiagnosed proportion and treatment, Canada, 2019. Can Comm Dis Rep. 2022;48:540–9.